PRESS RELEASES

Date Title View
Toggle Summary Chimerix to Present at Cowen and Company 40th Annual Health Care Conference
DURHAM, N.C. , Feb. 26, 2020 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, today announced that Mike Sherman , Chief Executive Officer, will present a corporate overview at the
View HTML
Toggle Summary Chimerix Reports Fourth Quarter and Year End 2019 Financial Results and Provides Operational Update
- Successful DSTAT End of Phase 2 Meeting with FDA Confirms Phase 3 Readiness; First Patient Visit Expected mid-2020 in 1L AML - - Brincidofovir pre-NDA Meeting Scheduled with FDA, on Track for mid-2020 NDA Filing - – Conference Call at 8:30 a.m. ET Today – DURHAM, N.C. , Feb.
View HTML
Toggle Summary Chimerix Appoints Pratik S. Multani, M.D., to Board of Directors
DURHAM, N.C. , Feb. 24, 2020 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, today announced the appointment of Pratik S. Multani , M.D., to its Board of Directors, effective
View HTML
Toggle Summary Chimerix to Report Fourth Quarter and Year End 2019 Financial Results and Provide an Operational Update on February 25, 2020
DURHAM, N.C. , Feb. 18, 2020 (GLOBE NEWSWIRE) -- Chimerix  (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, today announced that it will host a live conference call and audio webcast on Tuesday, February 25,
View HTML
Toggle Summary Chimerix Presents Data Supporting Brincidofovir as a Potential Treatment for Smallpox at 2020 American Society for Microbiology Biothreats Meeting
Brincidofovir demonstrated a statistically significant survival advantage in two well-characterized animal models of lethal orthopoxvirus infection DURHAM, N.C. , Jan. 29, 2020 (GLOBE NEWSWIRE) -- Chimerix  (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of
View HTML
Toggle Summary Chimerix Presents Updated Results from Phase 2 Clinical Trial of DSTAT in Refractory Myelodysplastic Syndrome and Acute Myeloid Leukemia at American Society of Hematology Annual Meeting
DURHAM, N.C. , Dec. 10, 2019 (GLOBE NEWSWIRE) -- Chimerix, Inc. (Nasdaq: CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, today announced that data relating to its dociparstat sodium (DSTAT) program, formerly known
View HTML
Toggle Summary Chimerix Announces Third Quarter 2019 Financial Results and Provides Operational Update
–  Final Data from Phase 2 Randomized Trial of DSTAT in First-line AML Support Enhanced Durability of Response, Event-free Survival and Overall Survival Benefit – – End of Phase 2 Meeting for Dociparstat (DSTAT) and Pre-NDA Meeting for Brincidofovir (BCV) Anticipated during First Quarter 2020 – –
View HTML
Toggle Summary Chimerix to Present at Upcoming Investor Conferences
DURHAM, N.C. , Nov. 04, 2019 (GLOBE NEWSWIRE) -- Chimerix, Inc. (Nasdaq: CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, today announced that management will present at two upcoming investor conferences in November.
View HTML
Toggle Summary Chimerix to Announce Third Quarter 2019 Financial Results and Provide an Operational Update on November 5, 2019
DURHAM, N.C. , Oct. 29, 2019 (GLOBE NEWSWIRE) -- Chimerix, Inc. (Nasdaq: CMRX), a biopharmaceutical company focused on accelerating the development of innovative medicines to treat patients with cancer and other serious diseases, today announced that it will host a live conference call and audio
View HTML
Toggle Summary Chimerix Announces Exclusive Global License Agreement with SymBio Pharmaceuticals for Brincidofovir
Includes All Human Indications Excluding Prevention and Treatment of Smallpox Chimerix to Receive up to $180 Million in Potential Clinical, Regulatory, and Commercial Milestones and is Eligible for Double Digit Royalties DURHAM, N.C. , Sept. 30, 2019 (GLOBE NEWSWIRE) -- Chimerix  (NASDAQ:CMRX), a
View HTML